Compounds > riamilovir
Page last updated: 2024-11-10

riamilovir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3113817
CHEMBL ID1618116
SCHEMBL ID18199177
MeSH IDM0534122

Synonyms (28)

Synonym
OPREA1_478576
OPREA1_193144
triazavirin ,
AKOS000637364
7-methylsulfanyl-3-nitro-6h-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one
123606-06-4
7-(methylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(1h)-one
STL363196
CHEMBL1618116
unii-f2htg1mh2d
triazavirin [who-dd]
riamilovir [inn]
riamilovir
DTXSID40389402
SCHEMBL18199177
riamilovir [inn]
(1,2,4)triazolo(5,1-c)(1,2,4)triazin-4(6h)-one, 7-(methylthio)-3-nitro
F2HTG1MH2D ,
7-(methylthio)-3-nitro(1,2,4)triazolo(5,1-c)(1,2,4)triazin-4(6h)-one
riamilovir [who-dd]
Q4462924
4(1h)-one
7-(methylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-
DB15622
F81714
[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(6h)-one, 7-(methylthio)-3-nitro-
7-(methylthio)-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(6h)-one
gtpl11996

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The authors present materials on experimental basis of approximate safe level of exposure to new anti-flu medication Triazavirin in air of workplace."( [Basing approximate safe level of exposure to Triazavirin in air of workplace].
Bitti, MA; Cherkashchenko, OS; D'iakova, LI; Lukovnikova, LV; Sidorin, GI; Skhodkina, NI, 2009)		0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits."( Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
Charushin, V; Chupakhin, O; Deev, S; Deeva, E; Ivanov, A; Karpenko, I; Kiselev, O; Kochetkov, S; Kukhanova, M; Rusinov, V; Smirnova, O; Ulomsky, E; Yanvarev, D, 2010)		0.36

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits."( Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.
Charushin, V; Chupakhin, O; Deev, S; Deeva, E; Ivanov, A; Karpenko, I; Kiselev, O; Kochetkov, S; Kukhanova, M; Rusinov, V; Smirnova, O; Ulomsky, E; Yanvarev, D, 2010)		0.36
" It is established that conjugate 2 in comparison to individual levofloxacin and triazavirine has a higher relative bioavailability and lower rate of elimination, which can lead to improved effectiveness of therapy at reduced dose and frequency of drug administration."( [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate].
Blazhennikova, IV; Bykov, VN; Charushin, VN; Chupakhin, ON; Geĭbo, DS; Kotovskaia, SK; Kurliakova, AF; Nikiforov, AS; Rusinov, VL; Stepanov, AV, 2015)		0.42

Dosage Studied

ExcerptRelevanceReference
" The analysis of the clinical data showed that the optimal prescribed dosage was 250 mg 3 times a day."( [A new antiviral drug Triazavirin: results of phase II clinical trial].
Charushin, VN; Chupakhin, ON; Deeva, EG; Kiselev, AS; Kiselev, OI; Kozeletskaia, KN; Mel'nikova, TI; Rusinov, VL, )		0.13
" Experimental group consisted of 53 patients who, in addition to standard therapy, were prescribed "off-label" riamilovir at a daily dosage of 1250 mg for 5 days by the decision of the medical commission."( Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection.
Kasyanenko, KV; Kozlov, KV; Lapikov, II; Maltsev, OV; Zhdanov, KV, 2022)		1.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1753364Antiviral activity against pseudotyped recombinant vesicular stomatitis virus delta G Gn-Gc infected HEK293T cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1753362Selective index, ratio of CC50 for MDCK cells to IC50 for Hantaan 76-1182021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1753361Antiviral activity against Hantaan 76-118 pseudovirus infected in MDCK cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1753363Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1753360Cytotoxicity against MDCK cells by MTT assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1753365Selective index, ratio of CC50 for HEK293T cells to IC50 for antiviral activity against pseudotyped recombinant vesicular stomatitis virus delta G Gn-Gc infected HEK293T cells2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (9.52)29.6817
2010's12 (57.14)24.3611
2020's7 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.66 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews1 (4.55%)6.00%
Case Studies1 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other19 (86.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.4110benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		2.0610alkylamine
ribavirin
Rebetron: Rebetron is tradename		3.03401-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		4.31701,2,3-triazole
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.11109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
chitosan
[no description available]		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease
[description not available]		05.4350
Break-Bone Fever
[description not available]		02.610
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		07.610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9840
Central European Encephalitis
[description not available]		02.5220
Diseases, Occupational
[description not available]		02.0510
Infections, Orthomyxoviridae
[description not available]		02.4620
Orthomyxoviridae Infections
Virus diseases caused by the ORTHOMYXOVIRIDAE.		02.4620
Grippe
[description not available]		02.0610
Influenza, Human
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.		02.0610